Table 2 Patient characteristics of the SHDB-AF database.
From: SHDB-AF: a Japanese Holter ECG database of atrial fibrillation
n | 128 | |
|---|---|---|
Age, mean (SD) | 68.0 (11.3) | |
Annotated, n (%) | 97 (75.8) | |
Female, n (%) | 47 (36.7) | |
Height (m), mean (SD) | 1.6 (0.1) | |
Weight (kg), mean (SD) | 62.4 (13.9) | |
BMI, mean (SD) | 23.0 (4.1) | |
AF type, n (%) | Paroxysmal (PAF) | 80 (62.5) |
Persistent (PerAF) | 15 (11.7) | |
Non-AF | 33 (25.8) | |
AF duration (months), median [IQR] | 9.0 [0.0,36.0] | |
First detected AF, n (%) | 20 (15.6) | |
History of atrial flutter, n (%) | 17 (13.3) | |
Previous ablation, n (%) | 41 (32.0) | |
Pacemaker on Holter, n (%) | 1 (0.8) | |
Antiarrhythmic drugs, n (%) | Bepridil | 11 (8.6) |
(non-beta blockers) | Amiodarone | 9 (7.0) |
Pilsicainide | 7 (5.5) | |
Verapamil | 3 (2.3) | |
Cibenzoline | 2 (1.6) | |
Frecainide | 2 (1.6) | |
Aprindine | 1 (0.8) | |
None | 93 (72.7) | |
Beta blockers, n (%) | Bisoprolol | 29 (22.7) |
Carvedilol | 9 (7.0) | |
Metoprolol | 1 (0.8) | |
None | 89(69.5) | |
Anticoagulation, n (%) | Edoxaban | 32 (25.2) |
Rivaroxaban | 14 (11.0) | |
Apixaban | 13 (10.2) | |
Warfarin | 5 (3.9) | |
Dabigatran | 2 (1.6) | |
None | 61 (48.0) | |
Comorbidities, n (%) | Hypertension | 43 (33.6) |
Congestive Heart Failure | 15 (11.7) | |
Age >75 | 28 (21.9) | |
Diabetes | 8 (6.2) | |
Stroke | 19 (14.8) | |
Vascular diseases | 15 (11.7) | |
